The Potential of cfDNA as Biomarker: Opportunities and Challenges for Neurodegenerative Diseases
Journal of Molecular Neuroscience,
Год журнала:
2025,
Номер
75(1)
Опубликована: Март 13, 2025
Abstract
Neurodegenerative
disorders,
including
Alzheimer’s
disease
(AD),
Parkinson’s
(PD),
multiple
sclerosis
(MS),
and
amyotrophic
lateral
(ALS),
are
characterized
by
the
progressive
gradual
degeneration
of
neurons.
The
prevalence
rates
these
disorders
rise
significantly
with
age.
As
life
spans
continue
to
increase
in
many
countries,
number
cases
is
expected
grow
foreseeable
future.
Early
precise
diagnosis,
along
appropriate
surveillance,
continues
pose
a
challenge.
high
heterogeneity
neurodegenerative
diseases
calls
for
more
accurate
definitive
biomarkers
improve
clinical
therapy.
Cell-free
DNA
(cfDNA),
fragmented
released
into
bodily
fluids
via
apoptosis,
necrosis,
or
active
secretion,
has
emerged
as
promising
non-invasive
diagnostic
tool
various
diseases.
cfDNA
can
serve
an
indicator
ongoing
cellular
damage
mortality,
neuronal
loss,
may
provide
valuable
insights
processes,
progression,
therapeutic
responses.
This
review
will
first
cover
key
aspects
then
examine
recent
advances
its
potential
use
biomarker
disorders.
Язык: Английский
Liquid biopsy: an emerging field with new opportunities for cancer diagnosis and prognosis
Asia-Pacific Journal of Oncology,
Год журнала:
2025,
Номер
unknown, С. 9 - 17
Опубликована: Янв. 14, 2025
Cancer
grades
among
the
deadliest
diseases,
globally
causing
death
of
a
over
million
people
each
year.
Early
diagnosis
has
been
considered
ideal
for
efficient
treatment
as
during
later
stages
chances
become
limited.
However,
gold
standard
tissue
biopsy
various
limitation
instance,
late-stage
and
its
intrusive
operation
making
it
unfit
repeated
sampling.
Scientists
are
passionately
looking
new
technologies
techniques
cancer
prognosis.
Liquid
emerged
diagnostic
prognostic
tool
cancer,
that
relies
on
body
fluids
to
identify
biomarkers
cancer.
It
offers
advantages
like
non-invasive
operation,
timely
detection,
amenable
sampling,
covers
tumor
heterogeneity.
Wide
attention
garnered
by
liquid
is
undergoing
rapid
progress
in
list
target
biomarkers.
The
most
common
circulating
cells,
DNA,
exosomes,
educated
platelets,
non-coding
RNAs
(miRNA,
lncRNA
etc.).
Each
these
have
unique
advantages,
indeed
technology
future
with
clinical
utility.
In
this
article,
we
tried
provide
thorough
introduction
markers,
highlighted
deployed
biopsy,
briefly
overview
their
implications
indispensable
entities
diverse
types
Moreover,
discussed
prospects
revolutionary
realm
treatment.
Язык: Английский
Wide-spectrum profiling of plasma cell-free RNA and the potential for health-monitoring
RNA Biology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 20, 2025
Circulating
cell-free
RNA
(cfRNA)
has
emerged
as
a
promising
analyte
for
disease
detection.
However,
the
comprehensive
profiling
of
diverse
cfRNA
types
remains
under-characterized.
Here,
we
applied
new
wide-spectrum
sequencing
method
and
simultaneously
captured
rRNA,
tRNA,
mRNA,
miRNA,
lncRNA,
all
mitochondrial
RNA.
The
compositions,
size
distributions,
highly
abundant
genes
were
analyzed
each
type
cfRNA.
We
depicted
cell
origin
profiles
66
generally
healthy
individuals
found
that
BMI
showed
significant
impact
on
kidney-derived
proportion.
Three
with
some
liver
problems
identified
because
relatively
high
levels
hepatocyte-specific
abundance
different
types,
including
miRNA
significantly
correlated
function
test
results.
individual
variances
enriched
in
pathways
associated
common
diseases
such
diseases,
virus
infections,
cancers,
metabolic
diseases.
This
study
provided
displayed
potential
biomarker
health
monitoring.
Язык: Английский
Molecular testing and targeting for solid tumors with CNS metastases
Journal of Neuro-Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 3, 2025
Язык: Английский
The impact of liquid biopsy in breast cancer: Redefining the landscape of non-invasive precision oncology.
The Journal of Liquid Biopsy,
Год журнала:
2025,
Номер
unknown, С. 100299 - 100299
Опубликована: Май 1, 2025
Язык: Английский
Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(18), С. 9982 - 9982
Опубликована: Сен. 16, 2024
The
potential
of
RNA-based
liquid
biopsy
is
increasingly
being
recognized
in
diffuse
large
B-cell
lymphoma
(DLBCL),
the
most
common
subtype
non-Hodgkin's
lymphoma.
This
study
explores
cell-free
transcriptome
a
humanized
DLBCL
patient-derived
tumor
xenograft
(PDTX)
model.
Blood
plasma
samples
(n
=
171)
derived
from
PDTX
model,
including
27
(HIS)
PDTX,
8
HIS
non-PDTX,
and
21
non-HIS
non-obese
diabetic
(NOD)-scid
IL2Rgnull
(NSG)
mice
were
collected
during
humanization,
xenografting,
treatment,
sacrifice.
treated
with
either
rituximab,
cyclophosphamide,
doxorubicin,
vincristine,
prednisone
(R-CHOP),
CD20-targeted
human
IFNα2-based
AcTaferon
combined
CHOP
(huCD20-Fc-AFN-CHOP),
or
phosphate-buffered
saline
(PBS).
RNA
was
extracted
using
miRNeasy
serum/plasma
kit
sequenced
on
NovaSeq
6000
platform.
sequencing
data
formalin-fixed
paraffin-embedded
(FFPE)
tissue
blood
original
patient
included.
Flow
cytometry
performed
immune
cells
isolated
whole
blood,
spleen,
bone
marrow.
Bulk
deconvolution
Tabula
Sapiens
v1
basis
matrix.
Both
R-CHOP
huCD20-Fc-AFN-CHOP
able
to
control
growth
mice.
Xenograft
volume
strongly
associated
circulating
(ctRNA)
concentration
(
Язык: Английский